Sponsors of investigational human immune globulin intravenous products need to show a rate of serious infections of less than one per person-year in pivotal clinical trials to sufficiently demonstrate efficacy, according to guidance from the FDA's Center for Biologics Evaluation and Research. The guidelines also review the various study-design strategies that may work for such trials.

Full Story:

Related Summaries